Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 Diabetes
| Status: | Completed |
|---|---|
| Conditions: | Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 75 |
| Updated: | 4/21/2016 |
| Start Date: | September 2009 |
| End Date: | September 2011 |
Use of Continuous Glucose Monitoring With Ambulatory Glucose Profile Analysis to Demonstrate the Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 Diabetes
The purpose of this study is to obtain continuous glucose monitoring (CGM) data from
individuals taking Welchol compared to placebo. The CGM data will determine the effect on
glucose control of adding Welchol to an anti-diabetic medication regimen.
individuals taking Welchol compared to placebo. The CGM data will determine the effect on
glucose control of adding Welchol to an anti-diabetic medication regimen.
To understand the effect of the addition of colesevelam HCl to oral agent therapy in
individuals with type 2 diabetes on glycemic control by utilizing a novel technology,
continuous glucose monitoring with ambulatory glucose profile analysis. To date there are no
studies of this compound that have employed continuous glucose monitoring (CGM) with
ambulatory glucose profile (AGP) analysis to obtain data that will detail the diurnal
glucose patterns associated with this therapy. We plan to employ CGM at critical points
throughout the study. AGP analysis will enable rapid assessment of the clinical status of
the subject. Using statistically stable estimates of hourly values represented by five
percentile curves AGP depicts glucose exposure, variability and stability. Previously, we
have used AGP analysis to characterize glucose perturbations in individuals ranging from
normal glucose tolerance to overt type 2 diabetes.
individuals with type 2 diabetes on glycemic control by utilizing a novel technology,
continuous glucose monitoring with ambulatory glucose profile analysis. To date there are no
studies of this compound that have employed continuous glucose monitoring (CGM) with
ambulatory glucose profile (AGP) analysis to obtain data that will detail the diurnal
glucose patterns associated with this therapy. We plan to employ CGM at critical points
throughout the study. AGP analysis will enable rapid assessment of the clinical status of
the subject. Using statistically stable estimates of hourly values represented by five
percentile curves AGP depicts glucose exposure, variability and stability. Previously, we
have used AGP analysis to characterize glucose perturbations in individuals ranging from
normal glucose tolerance to overt type 2 diabetes.
Inclusion Criteria:
- Male or female subjects ≥18 and ≤75 years of age
- Clinical diagnosis of type 2 diabetes
- Currently treated with metformin, a sulfonylurea, or combination
metformin/sulfonylurea; stable dose for ≥3 months
- HbA1c of 7.0-9.0% inclusive
- If taking lipid lowering medications, stable dose for >30 days
Exclusion Criteria:
- Taken oral or injected prednisone or cortisone medications in the previous 30 days.
(Topical or inhaled steroids will not be considered excluded medications.)
- Current use of insulin or TZD's, or incretins
- LDL <70 mg/dL
- Serum triglycerides >500 mg/dL
- History of hypertriglyceridemia-induced pancreatitis
- History of gastrointestinal disorder such as dysphagia, swallowing disorder,
intestinal motility disorder or prior bowel obstruction
- History or presence of any severe medical or psychological condition or chronic
conditions/infections that in the opinion of the Investigator would compromise the
subject's safety or successful participation in the study
- Unable to follow the study protocol
- Unable to speak, read and write in English
- Pregnant, planning to become pregnant, breast feeding
We found this trial at
1
site
Click here to add this to my saved trials
